NCT03324243View on ClinicalTrials.gov

A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Relapsed/Refractory FLT3-mutated AML
Interventions
DRUG

Crenolanib

66.7 mg/m2 three times a day (TID)

DRUG

Fludarabine

30 mg/m2/day, intravenous infusions over 30 mins.

DRUG

Cytarabine

2000 mg/m2/day, intravenous infusions over 1-3 hours.

Sponsors
All Listed Sponsors
lead

Arog Pharmaceuticals, Inc.

INDUSTRY